Head-To-Head Spine Fracture PMMA Trials Urged By FDA Guidance
This article was originally published in The Gray Sheet
Executive Summary
Two-year follow-up of patients in concurrent, randomized, controlled studies of PMMA-based bone cements for spinal insufficiency fractures is recommended by FDA to support 510(k) submissions
You may also be interested in...
BlueCross TEC Critiques Kyphoplasty; Kyphon Trial To Address Concerns
Kyphon is conducting a large, multi-center trial in response to concerns about the lack of controls in kyphoplasty trials to date, reflected most recently in a pair of BlueCross BlueShield Association Technology Evaluation Center assessments
BlueCross TEC Critiques Kyphoplasty; Kyphon Trial To Address Concerns
Kyphon is conducting a large, multi-center trial in response to concerns about the lack of controls in kyphoplasty trials to date, reflected most recently in a pair of BlueCross BlueShield Association Technology Evaluation Center assessments
Kyphoplasty Bone Cement Clearance Rounds Out Kyphon Line
Kyphon will market its kyphoplasty technology for fixation of osteoporosis-related vertebral compression fractures to referring physicians following recent approval of KyphX HV-R bone cement